Key takeaways from the FDA approval of dostarlimab-gxly in endometrial cancer – The Babak Lab

The Babak Lab shared on LinkedIn:

“FDA Expands Endometrial Cancer Treatment: The FDA has approved the expanded use of dostarlimab-gxly (Jemperli) alongside chemotherapy for treating advanced or recurrent endometrial cancer.

The RUBY trial results are promising, showing significant improvements in patient outcomes, including overall survival and progression-free survival.

Key takeaways:

• Clinical Trial: Efficacy evaluated in the RUBY trial (NCT03981796) with 494 patients.
• Outcomes: Significant improvement in overall survival (OS) and progression-free survival (PFS).
• Common Adverse Reactions: Anemia, increased creatinine, peripheral neuropathy, and more.
• Recommended Dose: 500 mg every 3 weeks for 6 cycles, followed by 1,000 mg every 6 weeks.

This marks a critical advancement in the fight against endometrial cancer, offering new hope to patients. Read more on the FDA website.

Stay informed on the latest developments in cancer treatment! Image source: The Sun U.S. Edition”

Source: The Babak Lab/LinkedIn